Literature DB >> 2137911

Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration.

A Supersaxo1, W R Hein, H Steffen.   

Abstract

The lymphatic absorption of four water-soluble compounds with different molecular weights (MW) was determined by measuring their cumulative recovery in lymph draining from the site of s.c. administration in sheep. The cumulative recoveries (% of dose, mean +/- SD; N = 3) were 4.0 +/- 1.5 (5-fluoro-2'-deoxyuridine, MW 246.2), 21.0 +/- 7.1 (inulin, MW 5200), 38.6 +/- 6.7 (cytochrome c, MW 12,300), and 59.5 +/- 7.7 [human recombinant interferon (rIFN) alpha-2a, MW 19,000], respectively. Our data show that in the investigated MW range, there is a linear relationship between the molecular weight and the proportion of the dose absorbed lymphatically. An increase in molecular weight results in an increased lymphatic absorption. Molecules with MW greater than 16,000 are absorbed mainly by the lymphatics which drain the application site. The knowledge gained in this investigation may help to improve the mode of administration and therapeutic efficacy of endogenous proteins whose targets are lymphoid cells (e.g., interferons, interleukins). Practical implications for the clinical use of such proteins are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137911     DOI: 10.1023/a:1015880819328

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  The output of cells in lymph from the popliteal node of sheep.

Authors:  J G HALL; B MORRIS
Journal:  Q J Exp Physiol Cogn Med Sci       Date:  1962-10

Review 2.  Roles of interferon produced in physiological conditions. A speculative review.

Authors:  V Bocci
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

3.  Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application.

Authors:  A Supersaxo; W Hein; H Gallati; H Steffen
Journal:  Pharm Res       Date:  1988-08       Impact factor: 4.200

Review 4.  Differences in lymphatic and blood capillary permeability: ultrastructural-functional correlations.

Authors:  C C O'Morchoe; P J O'Morchoe
Journal:  Lymphology       Date:  1987-12       Impact factor: 1.286

Review 5.  The human interferons--from protein purification and sequence to cloning and expression in bacteria: before, between, and beyond.

Authors:  S Pestka
Journal:  Arch Biochem Biophys       Date:  1983-02-15       Impact factor: 4.013

6.  [Interferon: A greatly simplified immuno enzyme determination with two monoclonal antibodies].

Authors:  H Gallati
Journal:  J Clin Chem Clin Biochem       Date:  1982-12

7.  The physiological interferon response.

Authors:  V Bocci
Journal:  Immunol Today       Date:  1985-01

8.  Monoclonal antitumor antibodies in the lymphatics.

Authors:  J N Weinstein; M A Steller; D G Covell; O D Holton; A M Keenan; S M Sieber; R J Parker
Journal:  Cancer Treat Rep       Date:  1984-01

9.  Studies on the permeability of lymphatic capillaries.

Authors:  L V Leak
Journal:  J Cell Biol       Date:  1971-08       Impact factor: 10.539

  9 in total
  88 in total

1.  Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model.

Authors:  S A Charman; D N McLennan; G A Edwards; C J Porter
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

Review 2.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

Review 3.  Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.

Authors:  Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-15       Impact factor: 2.745

4.  Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Stephanie H Kim; Karl G Csaky; Nam Sun Wang; Robert J Lutz
Journal:  Pharm Res       Date:  2007-08-03       Impact factor: 4.200

Review 5.  Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins.

Authors:  Iftekhar Mahmood; Martin D Green
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Population pharmacokinetics of onercept in healthy subjects.

Authors:  Sophie Glatt; Eliane Fuseau; Mauro Buraglio; Quyen T X Nguyen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep.

Authors:  Danielle N McLennan; Christopher J H Porter; Glenn A Edwards; Anne C Heatherington; Steven W Martin; Susan A Charman
Journal:  Pharm Res       Date:  2006-08-09       Impact factor: 4.200

8.  Subcutaneous Site-of-Absorption Study with the Monoclonal Antibody Tocilizumab in Minipigs: Administration Behind Ear Translates Best to Humans.

Authors:  Wolfgang F Richter; Hans-Peter Grimm; Marie-Hélène Gouy; Susi Søgaard; Caroline Kreuzer; Uwe Wessels; Dragomir Draganov; Chris Muenzer; Tonio Hoche
Journal:  AAPS J       Date:  2020-04-03       Impact factor: 4.009

9.  Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery.

Authors:  Deepa A Rao; M Laird Forrest; Adam W G Alani; Glen S Kwon; Joseph R Robinson
Journal:  J Pharm Sci       Date:  2010-04       Impact factor: 3.534

10.  In vitro/in vivo correlation for 14C-methylated lysozyme release from poly(ether-ester) microspheres.

Authors:  R van Dijkhuizen-Radersma; S J Wright; L M Taylor; B A John; K de Groot; J M Bezemer
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.